The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting & Pre-Conference Programs (SITC 2022) are taking place Nov. 8–12, 2022, at the Boston Convention and Exhibition Center in Boston. BBCR will be attending the conference this week and is looking forward to reporting back on conference events. Are you attending? Please let us know! […]
Tagged: SITC
BBCR is attending this week’s SITC 37th Annual Meeting & Pre-Conference Program and we will reporting on conference events soon.
November 9th, 2022 | SITCCategories
- Biomarkers & Surrogate Endpoints
- Company News
- Drug Development
- Due Diligence
- Early Clinical Development
- Industry News
- Medical Affairs and Clinical Research
- Miscellaneous
- Orphan Diseases
- Pre-IND
- Precision Medicine
- Rare Disease
- Real World Evidence
- Regulatory
- Regulatory Affairs
- Strategy and TPP
- Translation Medicine and Epigenetics
- Trial Management
- Trial Rescue
Recent Posts
- BBCR’s team of experts help clients match treatments to rare genetic conditions and unsolved diseases, then work collaboratively with a product developer on the best plan to market. To learn more, visit bbcrconsulting.com.
- Drug repurposing accelerates the path from discovery to the clinic, offering particular promise for rare, neglected, oncologic, and neurodegenerative diseases. Learn how we can help at bbcrconsulting.com
- Is Your Drug Development Strategy Built for Tomorrow’s Success?
- BBCR assists companies with the identification and adoption of biomarkers, now a routine part of drug development, and especially valuable in rare disease and precision medicine product development. Reach out to us to learn how we can assist with your development project.
- Partnering with BBCR Consulting means gaining the support of a specialized team committed to making the clinical trial process more efficient.